Four Pharma companies get licenses for anti-HIV drugs

New licenses were granted by MPP to seven generic drug makers, of which 4 were Indian. Cipla is the new entrant.


The agreement will help generic companies expand market size for these advanced AIDS therapies

Medicines Patent Pool(MPP), a United Nations-backed organization that facilitates cheaper HIV treatment in developing countries, has announced a fresh agreement to manufacture two anti-Aids medicines with seven generic drug makers, four of which are Indian firms, which are  Aurobindo, Cipla, Emcure and Micro Labs.

MPP does sign agreements with innovator companies to share new drug patents in a pool that can be accessed by generic companies to manufacture and sell cheaper versions of those anti-HIV drugs. And generic companies seek sub-licenses for these drug patents.

In the latest agreement, four Indian companies were given manufacturing licenses for next generation or second line anti-HIV treatments - Bristol Myers Squibbs' atanazavir and ViiV Healthcare's dolutegravir.

The WHO estimates that there will be more than one million people on second-line treatment by 2016 and many more will need access to the same. MPP currently has nine anti-HIV drug patents in its pool and ten generic manufacturing sub-licensees.

Indian firms Aurobindo and Emcure have been associated with MPP and have 5-6 anti-HIV drug licenses. The new agreement to manufacture atanazavir adds to their existing portfolio.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email